---

Exploring uterine fibroids and its treatment in current scenario

Full Text PDF

---

Review Article

Author Details : Isatou Drammeh, Rajni Yadav*, Mahendra Kumar Sahu

Volume : 8, Issue : 3, Year : 2023

Article Page : 143-148

https://doi.org/10.18231/j.ijcaap.2023.025

Suggest article by email

Get Permission

Abstract

Uterine Fibroids (leiomyoma) are made of muscle cells and other grow tissues grow in and around of the wall of the uterus. Uterine fibroids benign tumors in women reproduction age worldwide. Many are discovered incidentally on clinically examination. Approximately 30% of women with uterine fibroids will present with severe symptoms, which can include abdominal uterine bleeding, anemia, pelvic pain and constipation. Infertility and recurrent miscarriage may also be symptoms of fibroids, depending on their location and size, especially for sub mucous and intramural myelomas distorting the uterine cavity. Current option for symptomatic fibroid treatment includes expectant medical and surgical management radiology procedures. Ultrasound can be done, when a patient is symptomatic of uterine fibroids. Fibroids are generally classified by their location; intramural fibroids, subserosal fibroids, submucosal fibroids. The cause of uterine fibroids is unknown, But research and clinical experience proposes that genetics, hormonal imbalance, other growth factor and extracellular matrix accumulation could be the contributing factors .Although uterine fibroids are usually not dangerous, they can cause discomfort and lead to complication such as, drop in red blood cell (anemia) which causes fatigue from heavy bleeding. Our aim is to highlight the new treatments and advancements in treating uterine fibroids. Later we have also highlighted the future advancements and innovations that are used in developed countries for same.
 

Keywords: Uterine fibroids, Causes of uterine fibroids, Treatment and advancements in uterine fibroids

How to cite : Drammeh I , Yadav R, Sahu M K, Exploring uterine fibroids and its treatment in current scenario. IP Int J Compr Adv Pharmacol 2023;8(3):143-148

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.